Dental identification of unknown bodies through antemortem data taken by non-dental X-rays. Case reports.

The dental radiographic comparison is one of the most reliable and scientifically accepted methods for body identification (ID). The heterogeneity between AM (ante mortem) and PM (postmortem) x-rays images continues to stand as an issue for the forensic odontologist. Casual dental findings on X-rays for investigation of other structures than teeth or maxillaries, could eventually be a relevant source of dental data for the ID especially when AM dental files or X-rays are lacking. Two cases are reported in which the body ID was achieved through the comparison of PM dental X-rays with dental images obtained by radiographies of other structures (e.g. X-rays of the skull or cervical spine). These cases highlight that these occasional dental findings might provide sufficient evidence for a body identification. In the collection of AM data of missing people, the collection of all available records and radiographies of the head, neck and chest should be carefully reviewed by forensic odontologists, seeking for any available dental data.

Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.

Single-agent gemcitabine has been established as standard treatment for advanced pancreatic cancer since clinical studies have shown an improvement in overall survival and significant clinical benefit when compared to the best supportive care despite low overall objective response. Several phase II studies have tested other single agents and different gemcitabine-based regimens in pancreatic cancer, but both response and survival rates have remained low. Irinotecan, a topoisomerase I inhibitor currently approved for the treatment of metastatic colon cancer, has also demonstrated improved response rate in patients with pancreatic cancer. Our purpose was to determine the activity and toxicity of this regimen in patients with unresectable or metastatic pancreatic cancer. Patients with histologically confirmed pancreatic adenocarcinoma received gemcitabine 1000 mg/m2 plus irinotecan 100 mg/m2 IV on days 1, 8, and 15 of a 28-day cycle for 6-8 months. From February 2004 to April 2006, 33 patients were entered into this study, 32 of whom were evaluable for treatment response, toxicity, median time to progression, and median survival. Characteristics included a median age of 63 years (range 41-79), 21 males (64%), and 12 females (36%). One patient discontinued treatment due to adverse effects. The total number of cycles administered was 188 and the median number of cycles for patients was 5.6 (range 2-7). Thirty-two patients were assessable for toxicity and response. Grade 3 hematological toxicity occurred in 9% of patients and was primarily neutropenia. No grade >2 gastrointestinal toxicities or death due to treatment were observed. The most frequent nonhematological adverse event was fatigue. Ten patients responded to treatment with two complete responses (6.3%) and eight partial responses (25.0%), for an overall response rate of 31.3%; 11 patients achieved stable disease (34.3%). The median time to tumor progression and the median survival were 9.2 (95% CI: 6.0-12.4) and 11.8 (95% CI: 7.7-15.9) months, respectively, with a 2-year survival of 22%. On the basis of this trial, the combination of gemcitabine plus irinotecan, administered in a weekly schedule and at this dose, is well tolerated and offers encouraging activity in the treatment of advanced and/or metastatic pancreatic cancer.

The age estimation practice related to illegal unaccompanied minors immigration in Italy.

The migrants arrived to the Italian coasts in 2016 were 181.436, 18% more than the previous year and 6% more than the highest number ever since. An "unaccompanied minor" (UAM) is a third-country national or a stateless person under eighteen years of age, who arrives on the territory of the Member State unaccompanied by an adult responsible for him/her whether by law or by the practice of the Member State concerned, and for as long as he or she is not effectively taken into the care of such a person; it includes a minor who is left unaccompanied after he/she entered the territory of the Member States. As many as 95.985 UAMs applied for international protection in an EU member country just in 2015, almost four times the number registered in the previous year. The UAMs arrived in Italy were 28.283 in 2016; 94% of them were males, 92% unaccompanied, 8% of them under 15; the 53,6% is 17; the individuals between 16 and 17 are instead the 82%. Many of them (50%), 6561 in 2016, escaped from the sanctuaries, thus avoiding to be formally identified and registered in Italy in the attempt to reach more easily northern Europe countries, since The Dublin Regulations (2003) state that the asylum application should be held in the EU country of entrance or where parents reside. The age assessment procedures can therefore be considered as a relevant task that weighs in on the shoulders of the forensic experts with all the related issues and the coming of age is the important threshold. In the EU laws on asylum, the minors are considered as one of the groups of vulnerable persons towards whom Member States have specific obligations. A proper EU common formal regulation in the matter of age estimation procedures still lacks. According to the Italian legal framework in the matter, a medical examination should have been always performed but a new law completely changed the approach to the procedures of age estimation of the migrant (excluding the criminal cases) with a better adherence to the notions and concepts of vulnerability and psychological and social maturity.

Day to day issues in the forensic identification practice related to illegal immigration in Italy.

The migratory flows to Europe from the African countries, Asia and Middle East, have hugely intensified in the recent years. In 2016, more than 98,000 out of a total of 260,000 migrants across the Mediterranean Sea arrived in Italy and in May 2017, the trend of arrivals is: Italy +576%; Greece -39% compared to previous years. Some migrants die before touching the sole of the European continent, during the crossing, often afforded with ships, made available by unscrupulous smugglers or criminal organizations, which are unsuitable for this type of transportation. The tremendous occurrence of migrant casualties during the Mediterranean Sea crossing remains underestimated and nobody, country officers or databank, can provide a reliable number of dead bodies in such a large and now, endemic phenomenon. Forensic officers, who intervened to examine migrants' corpses, are ideally required to perform the usual activity and to answer the routine questions about the causes of death by detecting signs of possible crimes and body identification. In practice, several specific issues and limits challenge the activity of the forensic professionals addressed to ascertain both circumstances of death and possible related crimes and the identity of the corpses. Generally speaking, in case of examining up to a few dead bodies in Italy, a complete autopsy is performed, whilst, when several tens or hundreds of corpses are recovered, the lack of resources on one hand and clearer clues on incident, connected crimes, and cause of deaths on the other, push the public prosecutor to limit the request of complete autopsies. In some cases, the dead migrants were identified through visual recognition by relatives, friends, or travel companions. The DVI Interpol protocol is never completely applied to dead migrants for several reasons, mainly for the huge difficulties in retrieving AM data of the missing persons and for some limitations affecting both the primary and the secondary identifiers. The few chances of identification by dental data are further reduced by the systematic lack of an odontologist among the forensic teams charged of the PM; valuable dental data for body identification or for constructing the biological profile of the missing person (age, ancestry, country of provenance/residence, etc.) are likely to be overlooked. This approach implies a clear disparity with the approach applied when corpses of citizens of the EU or other developed countries are involved and undergo identification. The dead migrants' identification activity should be reconsidered for an improvement in the common international effort in accordance to an approach more respectful toward the legal rights and dignity of the dead migrants and their families.

[Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)]. / Trattamento del carcinoma prostatico in fase avanzata con LH-RH analogo in forma depot (ICI 118630).

Twenty-two patients with newly diagnosed advanced prostatic cancer treated with once-monthly subcutaneous injection of a long acting depot preparation of a new luteinizing hormone-releasing hormone superagonist (ICI 118,630) with a minimum follow-up duration of 6 months are reported. The partial regression rate was 45.4% while 36.4% of the patients had stable disease and only 18.2% have progressed by P.O.N.CA.P. criteria. Patient acceptance was excellent and side effects occurring during treatment (hot flashes, gynecomastia, etc.) were minimal. The depot preparation of the LH-RH analogue was well tolerated and no side effects required dose modifications or removal from the study. Depot LH-RH analogue may become an alternative treatment for patients with advanced prostatic cancer if further clinical evolutions will confirm that the response rate with LH-RH analogue is comparable to the conventional endocrine therapies.

[Nephrogenic adenoma. Presentation of 7 cases]. / Adenoma nefrogenico. Presentazione di sette casi.

Nephrogenic adenoma is a vesical lesion of uncertain pathogenesis. Histologically it is characterised by glandular-like aspects that take on the form of tiny tubules consisting of a single layer of cuboidal or columnar epithelium. The lesion was first described by Davis in 1949 and a year later Friedman and Kuhlembeck coined the term nephrogenic adenoma. Personal experience with seven cases of this lesion is reported here. Six of the seven cases occurred in the bladder, the remaining one in the prostatic urethra. Four patients reported prior surgery of the urinary ways, three suffered from recurrent cystitis, one had bladder stones while three were being followed up in our department for urothelial carcinoma. Diagnosis of nephrogenic adenoma was based on histopathological examination carried out on biopsy samples taken during urethrocystoscopy. The urothelial lesions were subjected to transurethral resection or endoscopic diathermocoagulation. All patients are being followed up and no recurrences have yet been reported.

[Nosocomial infections of the urinary tract in urology patients]. / Le infezioni nosocomiali delle vie urinarie nei pazienti urologici.

Researches effected in different nations have revealed that 5-12% of all hospitalized patients was affected with a nosocomial infection and that almost 1/3 of these were urinary tract infections. The hospitalized urological patients have a considerable proneness to contract a nosocomial urinary tract infection, because they are subjected to transurethral or suprapubic bladder catheterisms, to transurethral surgery and to the endoscopies, that are promoting maneuvers the urinary tract infections. Generally the Gram negative bacilli are the cause of hospital-acquired urinary tract infections, even if lately Gram positive bacilli (especially Streptococcus Faecalis or Enterococcus), "Gram negative Facultative pathogens" (Klebsiella, Providencia, Citrobacter, Serratia) and Fungi are very important. Considering the importance of these infections we have examined the incidence of the urinary tract infections of the hospitalized patients between January 1, 1986 and December 31, 1986 in our Urologic Institute. During the 12-month study interval there were 450 hospital admissions, and 45 patients were affected with a nosocomial urinary tract infection (10%). The females were affected at the rate of 6.7% of them, with an incidence of 4.7% among all patients with a positive urine culture; on the contrary the males were affected at the rate of 11.4% of them, equal to 19.0% of patients with a positive urine culture. We have noticed that among the responsible microorganisms for the nosocomial urinary tract infections, the group of the "Gram negative Facultative pathogens" was more frequent (40%), followed by Pseudomonas Aeruginosa and Candida species. So also in our Urologic Institute the modification of the responsible agents for the nosocomial urinary tract infections happened. The nosocomial infections after the discovery of the antibiotics were considered wiped out, on the contrary these infections are still an important problem of public health, so that efficaciously must be tackled.

Verrucous carcinoma in situ of the bladder, not associated with urinary schistosomiasis.

Verrucous carcinoma is a variant of well differentiated squamous cell carcinoma that rarely affects the bladder. The bladder localization of this carcinoma is usually associated with urinary schistosomiasis. In this work we report on a rare case of verrucous carcinoma of the bladder not associated with urinary schistosomiasis. To complete this study, analysis of DNA was carried out on the histologic sections of the tumour.

Low ureteral obstruction caused by umbilical ligament in a 37 year old man: a case report.

Arterial vascular anomalies rarely cause extrinsic ureteral obstruction and only 11 cases have been reported so far. This paper deals with an unusual extrinsic obstruction of the left ureter caused by a residue of the umbilical artery in a 37 years old man. The patient had left flank pain due to serious hydronephrosis on the same side. At operation a fibrous cord, a residue of the left umbilical artery, partially obstructed the distal left ureter. Partial left terminal ureterectomy with ureteroneocystostomy was performed. In the differential diagnosis of low extrinsic ureteral obstructions also the uncommon vascular anomalies of the umbilical artery should be taken into consideration.

Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.

The association between oxaliplatin and 5-fluorouracil (5-FU) has been extensively reported to improve prognosis of gastric cancer patients. The present study is aimed at evaluating response rate and the toxicity profile of the association with oxaliplatin, 5-FU/lecovorin and epirubicin in gastric cancer patients with locally advanced or metastatic disease. Thirty-six patients have been enrolled and 35 evaluated. The treatment schedule was oxaliplatin (100 mg m(-2)), 5-FU (400 mg m(-2)), leucovorin (40 mg m(-2)) and epirubicin (60 mg m(-2)) intravenously. administered every 3 weeks for 6 months, for a total of 185 therapy cycles . Response rate and toxicity were assessed according to the international WHO criteria. Every patient received a mean of 5.3 therapy cycles in a day-hospital setting. Sixteen of 35 patients (46%) showed an objective response, two complete response and 14 partial response. Median time to progression was 33 weeks with an overall median survival of 49 weeks. During the study, anaemia grade 3 and neutropenia grade 3 were observed in 9 and 11% of patients respectively. A grade 3 periferic sensorial neuropathy was observed in 6% of patients. No life threatening or cardiac toxicity was recorded. The regimen used showed anticancer activity against gastric carcinoma, a tolerable toxicity profile and excellent patient compliance.